Kornimate/medical-research-clean huggingface dataset:
effect of cannabis and cigarette smoking on oral mucosa

Conditions: Field Cancerization for Cannabis Smokers

Summary: the aim of this study is to detect p53 expression in clinically normal oral mucosa of cigarette smokers, simultaneous cigarette and cannabis smokers and non-smokers as a surrogate marker for field cancerization.

roles and responsibilities: 1. ali abd el wahed abd el fatah kotb (a.k.) operator, data enterer, assistant lecturer, oral and maxillofacial pathology, faculty of oral and dental medicine, cairo university, egypt. 2. professor dr. heba dahmoush (h.d.) main supervisor, data monitoring,auditing professor, oral and maxillofacial pathology, faculty of oral and dental medicine, cairo university, egypt. 3. eman desoky (e.d.) sample size calculation, statistician,faculty of oral and dental medicine, cairo university, egypt. 4. evidence based dentistry committee (cebd)help in reporting study protocol following spirit guidelines,faculty of oral and dental medicine, cairo university, egypt. 5. research ethics comittee (crec)protocol reviewer in order to protect the right, safety, dignity and well-being of the participants, faculty of oral and dental medicine, cairo university, egypt. 1- intervention: a.k. will collect specimens from cigarette smokers and simultaneous cigarette and cannabis smokers. then the expression of p53 as a marker for field cancerization will be investigated in formaline fixed paraffine embedded specimens of mucosal biopsies obtained from the oral mucosa of both groups. 2-comparator: mucosal biopsies from non smokers will be investigated as a copmaratitive to smokers group.

Eligibility criteria:
inclusion criteria: * frequent smokers (at least 10 cigarettes a day) for a period not less than 5 years. * simultaneous smokers to be included in the study must be frequent cigarette smokers (at least 10 cigarettes a day) for a period not less than 5 years plus frequent cannabis smoker (at least 3 times per week) for a period not less than 5 years. exclusion criteria: * exposure to other carcinogens. * un-clear smoking history. * medically compromised patients
intrathecal transplantation of autologous adipose tissue derived msc in the patients with spinal cord injury

Conditions: Spinal Cord Injury

Summary: the effect of intrathecal transplantation of autologous adipose tissue derived mesenchymal stem cells in the patients with spinal cord injury, phase i clinical study.


Eligibility criteria:
inclusion criteria: 1. patient who don't have any possiblity of improving neurological function despite performed the optimal treatment after spinal cord injury 2. no change in neurological function for 4weeks interval by at least 2 clincal medical specialists 3. patient who is able to give written informed consent of clinical trial about stemcells treatment exclusion criteria: 1. patient who is under 19 years and over 70years 2. patient who must use the mechanical ventilator 3. patient who have a history of malignant tumor within 5 years 4. patient who is having a infectious disease of including current hepatitis and hiv 5. patient who had the brain or spinal cord injury before the spinal cord injury (confirm subject's history from their medical history) 6. patient who is having a acute disease judged by principle investigator or having a fever over 38.0 ℃ at the vaccination day 7. patient who is having an anemia or thrombopenia 8. patient who is having an angina, myocardial infarct, myocardiopathy, obstructive vessel disease, chronic renal failure, glomerulopathy and chronic obstruent lung disease (confirm subject's history from their medical history) 9. patient who is having a congenital immune deficiency syndrome or aids (confirm subject's history from their medical history) 10. patient who is having an amyotrophia or joint atrophy 11. patient who is having an disturbanace of consciousness or dysphrasia 12. patient who is taking an immunosuppressive agents or corticosteroids agents or cytotoxic agents or needed administration 13. patient who have experienced another clinical trials within 3 months involving this clinical trial 14. patient who can't participate in this clinical trial having any opinion regarded as clinical significance judged by principle investigator

Keywords: autologous adipose tissue
curcumin and nanocurcumin in oral aphthous ulcer

Conditions: Recurrent Aphthous Ulcer; Recurrent Aphthous Stomatitis

Summary: recurrent aphthous ulcer is a painful inflammatory lesion with a high prevalence. since the etiology is not clear, several strategies have been proposed to reduce pain and severity of its symptoms. today, curcumin is considered as an herbal medicine with anti-inflammatory properties. treatment or control of various inflammatory diseases has been proposed, but its low solubility in water has reduced bioavailability, while the use of nanoparticle pharmaceutical techniques has been able to solve these problems. therefore, the aim of the present study was to evaluate the clinical efficacy of a new topical curcumin gel with nano-technology and compare it with 2% curcumin gel in patients with recurrent aphthous ulcers. this randomized clinical trial was performed on 48 patients assigned to two groups (nano-curcumin gel) and (curcumin gel). before treatment, the size of the wound and vas were measured. after intervention, the two variables were measured again on the fourth and seventh days , then the amount of improvement was quantitatively and qualitatively compared in the two groups and a significant level of less than 0.05 was considered.


Eligibility criteria:
inclusion criteria: * patients with minor and recurrent aphthous ulcer lesions within 48 hours and aphthous like lesions exclusion criteria: * wounds are in inaccessible areas (such as posterior palate). if a person suffers from systemic disease (through questioning the patient) patients with turmeric allergy and any type of gel used in this study. pregnant or lactating women .. accompany with other mucosal lesions. do not take any other medicine while taking intervention major or herpeti form of aphthous ulcer

Keywords: recurrent aphthous stomatitis curcumin nanocurcumin management
a cohort study with 100 subjects having a primary total knee replacement, taking pradax post discharge for ten days

Conditions: Thromboembolism

Summary: currently standard of care for preventing blood clots in total knee replacement patients is the drug fragmin which is a daily injection for 10 days after surgery. patients are in hospital for 3 to 5 days after total knee replacement surgery and patients are taught in hospital to do their injections. the investigators would like to introduce the drug pradax. pradax is a health canada approved once a day, oral drug that may prevent blood clots in the patient's leg. in this study the patient will receive the standard of care injection drug fragmin while in hospital but on discharge home the patient will take the oral drug pradax daily (2 tablets 110mg) for 10 days.

we will enroll one hundred patients who are scheduled to have a total knee replacement. if you have signed the consent form for this study you will receive the standard of care treatment for blood clots, which is a daily injection drug called fragmin. on the day of discharge from hospital study patients will receive a ten day supply of oral pradax. to be taken once a day. the orthopaedic research coordinator will call the study patients at post discharge day three and five to check on compliance and or concerns. all total knee replacement patients whether in study or not are seen in the orthopaedic clinic at post op day 10 for staple removal and again at the 6 week point, 3 month, and 6 month and 1 year point. standard of care x-rays are done also at these visits.

Eligibility criteria:
inclusion criteria: * patients are eligible for the study if they are adult age, being greater than 18 years of age and less than 95 years of age. they must have the indications for a total knee replacement and have sufficiently passed the medically necessary tests by their surgeon to warrant total knee replacement. exclusion criteria: * patients with active bleeding, or high risk of bleeding that contra-indicates the use of pradax * renal or liver contra-indication necessitating adjustments of its dose. * clinically significant liver disease, * concomitant use of proteus ace inhibitors * the use of the human immunitive deficiency virus * the use of fibrinolynic agents * planned intermittent pneumatic compression or requirement of ongoing anticoagulation therapy * pregnancy * breast-feeding.

Keywords: thrombosis total knee replacement
acell matristem pelvic floor matrix versus native tissue repair, comparative study

Conditions: Pelvic Organ Prolapse

Summary: the primary objective of this study is to assess the safety and effectiveness of matristem pelvic floor matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. patients are evaluated throughout a 3 year follow-up period.


Eligibility criteria:
inclusion criteria: * subject's leading edge of pop is at or beyond the hymen. at or beyond the hymen is defined as pop-q scores of ba ≥ 0 or bp ≥ 0 or c ≥ 0 (for prolapse of the apical compartment alone) or c ≥ -½ total vaginal length (for a multi-compartment prolapse that includes the apical compartment). * subject is seeking surgical intervention for symptomatic pop, which is defined as experiencing symptoms of vaginal bulging or pelvic heaviness. vaginal bulge or pelvic heaviness will be considered present if a subject responds "yes" (≥1) to pfdi-20, question 3. * subject or subject's legally authorized representative is willing to provide written informed consent. * subject is willing and able to comply with the follow-up regimen. exclusion criteria: * subject has a known hypersensitivity to porcine-based materials (relevant to subjects in matristem pelvic floor matrix group only). * subject is pregnant or plans to become pregnant during the study. * subject has an active or chronic systemic infection including any gynecologic infection, urinary tract infection (uti), or tissue necrosis. * subject has a known neurologic or medical condition affecting bladder function (e.g. multiple sclerosis, spinal cord injury, or stroke with residual neurologic deficit). * subject has chronic systemic pain syndrome (e.g. fibromyalgia, painful bladder syndrome). * subject has a systemic connective tissue disease (e.g., scleroderma, systemic lupus erythematous (sle), marfans syndrome, ehlers danhlos, collagenosis, polymyositis or polymyalgia rheumatica). * subject has uncontrolled diabetes mellitus (dm). * subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical). * subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area. * subject has taken systemic steroids (within the last month), immunosuppressive or immunomodulatory treatment (within the last 3 months). * subject is seeking obliterative vaginal surgery as treatment for pop (colpoclesis). * subject is not able to conform to the modified dorsal lithotomy position. * subject is currently participating in or plans to participate in another device or drug study during this study. * subject is to planning to undergo concurrent surgical treatment of prolapse using mesh other than the matristem pelvic floor matrix.

Keywords: pelvic organ prolapse matristem pelvic floor matrix acell native tissue repair
instrument assisted soft tissue mobilization effect on blood flow

Conditions: Asymptomatic Condition

Summary: this study is designed to evaluate the short term change in blood flow in the superficial human tissue layers after the application of 3 min graston instrumented assisted soft tissue mobilization on the plantar aspect of the foot and the trapezius muscle.

instrument assisted soft tissue mobilization (iastm) is a commonly used physical therapy intervention. graston ® technique is a form of iastm that requires completion of a certification course and utilizes specific stainless-steel tools. iastm has been found to improve range of motion, pain and patient reported function in pathological individuals. one method by which these improvements are thought to occur is by increasing blood flow. increased blood flow brings nutrients and oxygen to the area and is thought to contribute to tissue remodeling. there is very limited research investigating blood flow changes following iastm. in order to measure blood flow changes following iastm, doppler ultrasound may be used. there are no studies to our knowledge quantifying changes in blood flow following iastm using ultrasound. power doppler approximates perfusion by detecting a frequency shift from movement of red blood cells and color is then encoded proportionally to the number of red blood cells. power doppler imaging quantification (pdiq) is a feature of musculoskeletal ultrasound (msk) that compares the number of color pixels and the intensity of color within these pixels to grey scale pixels within a given image. the aim of this study is to determine if there is an increase in blood flow in the trapezius, plantar fascia and medial arch of the foot measured following iastm. blood flow was measured by using pdiq ratio in the doppler setting of msk ultrasound.

Eligibility criteria:
inclusion criteria: * a-symptomatic individuals over the age of 18 exclusion criteria: * anyone under 18 and anyone with any conditions contraindicated for iastm including compromised tissue integrity, deep vein thrombosis (dvt), area of infection in the treatment area, or acute fracture.

Keywords: instrument assisted soft tissue mobilization musculoskeletal ultrasound imaging bood circulation perception
an analysis of urinary proteases as biomarkers for hepatocellular carcinoma-101423

Conditions: Hepatocellular Carcinoma; Liver Disease

Summary: specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * ability and willingness to provide written informed consent * must be between 18-90 years of age at the time of consent * ability to provide urine specimen at protocol-defined timepoints * must have treatment interventions planned that are directly related to liver disease (excluding those assigned to group 3-controls) exclusion criteria: * suspected inability, e.g. unwillingness to comply with study procedures or unwillingness to provide written consent

Keywords: hcc liver disease without hcc
compliance and efficacy in mono and combination tablet study atacand/atacand plus

Conditions: Hypertension

Summary: to evaluate compliance and patients' satisfaction in mono and combination treatment of candesartan cilexetil (atacand)/ candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (atacand plus) in hypertension.


Eligibility criteria:
inclusion criteria: 1. patients who have consented to participation/data release in this study 2. patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision exclusion criteria: 1. secondary hypertension requiring therapy other than antihypertensive medication 2. patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician 3. women in pregnancy or lactation 4. patients enrolled in any other studies

Keywords: hypertension atacand/atacand plus combat compliance naturalistic observational
implementation of gla:d program in west virginians with osteoarthritis of the knee

Conditions: Osteoarthritis, Knee

Summary: this study will examine feasibility of implementing good life with osteoarthritis in denmark (gla:d) program in west virginians with osteoarthritis of the knee

using west virginia (wv) as an implementation site, this study will examine the feasibility of process implementation and effectiveness of the good life with osteoarthritis in denmark (gla:d) program in individuals with osteoarthritis of the knee (koa). specifically, the study will examine the feasibility and acceptability of the gla:d program in individuals with koa. this study will also assess the magnitude of changes in self-reported knee pain and functional impairments as well as physical performance in individuals who receive gla:d compared to those who receive control interventions consisting of disease-specific education and exercises for koa.

Eligibility criteria:
inclusion criteria: 1. between 45 to 90 years of age, 2. osteoarthritis of the knee (koa) (kellgren and lawrence grade 2, 3, or 4) confirmed by an orthopedic surgeon based on plain film radiographs and symptoms, and 3. recommendation by an orthopedic surgeon to pursue conservative management of koa. exclusion criteria: 1. prior joint replacement surgery in the ipsilateral knee, 2. known history of cognitive impairments or any neurodegenerative disease, 3. any other neurological or musculoskeletal pathologies that have resulted in permanent mobility deficits or functional impairments, 4. medical conditions that would preclude them from participating in exercise programs, and 5. inability to read and comprehend english.

Keywords: knee arthritis good life with osteoarthritis in denmark neuromuscular exercises
c1-inhibitor (inh) for refractory antibody mediated renal allograft rejection

Conditions: Antibody Mediated Rejection of Kidney Transplant

Summary: this is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor c1-inh (berinert) in an effort to protect the graft from ongoing antibody mediated injury. a maximum of 5 patients will be enrolled.


Eligibility criteria:
inclusion criteria: * kidney transplant with acute antibody mediated rejection refractory to standard therapy exclusion criteria: * patients with known intolerance of or anaphylaxis to berinert
the study of abatacept in combination with etanercept

Conditions: Rheumatoid Arthritis

Summary: the study was designed to look at the safety and efficacy of abatacept in combination with etanercept.


Eligibility criteria:
inclusion criteria: * all subjects who had completed the short term portion of im101-101.
an open label evaluation of the pharmacokinetics and safety of single dose intravenous azithromycin in preterm neonates

Conditions: Ureaplasma; Bacterial Infection

Summary: the purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of iv azithromycin in preterm neonates and confirm that the pharmacokinetics of azithromycin is similar in the 24-\<32 week and 32-\<37 week neonate. the dose of 10 mg/kg has been chosen on the basis of previous pediatric pharmacokinetic studies.

in vitro studies with azithromycin show good inhibitory activity against u. urealyticum. pharmacokinetic studies of azithromycin in older children show better tolerance, higher tissue concentration, fewer side effects, and fewer drug interactions, when compared to erythromycin. thus far, there have been no published data on the pharmacokinetic profile of azithromycin in neonates including low birth weight infants. however, the clinical pharmacology profile suggests a substantial therapeutic advantage of this drug in the newborn. to date, there are no data on the pk profile of iv azithromycin from whence rational dosing can be derived.

Eligibility criteria:
inclusion criteria: 1. 24 to 37 weeks gestational age 2. postnatal age 0 to 30 days 3. may require therapy with antibiotics/anti-infectives 4. have baseline hematology labs available (hemoglobin, hematocrit, white blood cell and differential and platelet count), which have been obtained within the previous 72 hours, as part of their standard of care 5. signed informed consent by the parent or guardian exclusion criteria: 1. clinically significant hepatic disease (alt or ast twice the normal value) 2. clinically significant anemia (hemoglobin \< 10 gm %) 3. neutropenia (absolute neutrophil count \< 500 cells/mm3) 4. clinically significant renal disease \[creatinine clearance twice the normal value, as calculated by the schwartz formula : length in cms x k (a constant) / s.cr (values for the constant are given in appendix 1)\] 5. cardiac rhythm abnormalities 6. critically ill patients 7. patients who are on or expected to be on the following concurrent medications carbamazepine, phenytoin, theophylline, digoxin, warfarin, ergot alkaloids, triazolam, cyclosporine, terfenadine, hexobarbital and antacids.

Keywords: bacterial infection azithromycin
ultrasound-guided ql block versus tap block for post-operative pain in lower abdominal surgeries

Conditions: Postoperative Pain

Summary: this study aims to compare the efficacy of ultrasound-guided ql block and tap block for postoperative pain management following lower abdominal surgeries.


Eligibility criteria:
inclusion criteria: * patients aged from 18 to 65 years old. * american society of anesthesiologists (asa) physical status i - ii. * patients scheduled for elective lower abdominal surgery. exclusion criteria: * patient refusal. * patients with bmi (body mass index) \> 35 kg.m-2 , \[morbid obesity\]. * patients with significant neurological, psychatric or neuromascular disease. * patients had local skin infection at the block injection site. * patients who operated under epidural and patient-controlled analgesia \[pca\]. * sensitivity to prescribed analgesia. * coagulopathies or those who had uncontrolled chronic medical disease \[e.g. diabetes mellitus, hypertension, or cardiac diseases\].
comparison of the effect on the glucose infusion rates between inhaled technosphere insulin and a subcutaneous injection of regular human insulin

Conditions: Healthy

Summary: a prospective, single center, open randomized, six way crossover study comparing the dose response effect of four different doses of technosphere insulin after pulmonary function delivery in comparison to s.c. injection of two different doses of regular human insulin.


Eligibility criteria:
inclusion criteria: * subjects must be in good health, as judge by brief history and physical examination. * sex: both, male and female. * age: 18-40 years. * body mass index: 18-27 kg/m2. * capability to reach peak inspiratory flow of \>41/sec measured by a computer assisted spirometry. * fev1 equal to or greater than 80% of predicted normal. exclusion criteria: * diabetes mellitus type 1 or type 2. * human insulin antibodies. * anamnestic history of hypersensitivity to the study medication or to drugs with similar chemical structures. * having a history of severe or multiple allergies. * treatment with any other investigational drug in the last three months before study entry. * progressive fatal disease. * history of significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and /or hematological disease. * having ongoing respiratory tract infection. * smoker defined as subjects with evidence or history of tobacco or nicotine use in the last year prior to entry in the study. * blood donation within the last 30 days. * a woman who is lactating. * pregnant women or women intending to become pregnant during the study. * a sexually active woman of childbearing age not actively practicing birth control or using medically accepted device or therapy. * a lack of compliance or other reasons, which prevent to the opinion of the investigator the participation of the subject in the study.

Keywords: healthy patients